Day 1 Afternoon: Peripheral Arterial & Chronic Limb Threatening Ischaemia (CLTI) - Tuesday, 25th April
Venue: Kensington 1 / Livestream 1
Time: 13:30 - 18:00
Potential Advances Consensus Update
Time: 13:30 - 15:20
| Anchor: | Roger Greenhalgh, London, United Kingdom |
| Moderator: | Dittmar Boeckler, Heidelberg, Germany |
Technical Advances
Time: 13:30 - 14:00
13:30 - 13:35
Endovascular deep venous arterialisation for attempted salvage of the desert foot
| Speaker: | Peter Schneider, San Francisco, United States |
13:35 - 13:40
Audience Participation & Discussion
13:40 - 13:45
The results of heparin-bonded ePTFE femoro-tibial bypasses in patients with critical limb ischaemia are competitive with those obtained with autologous saphenous vein
| Speaker: | Walter Dorigo |
13:45 - 13:50
Audience Participation & Discussion
Drug-Coated Sirolimus Devices
Time: 14:00 - 14:40
14:00 - 14:05
Update of the SELUTION BTK trial, using a sirolimus coated DCB in below the knee arteries
| Speaker: | Peter Gaines, Sheffield, United Kingdom |
14:05 - 14:10
Audience Participation & Discussion
14:10 - 14:15
Sirolimus coated balloon versus conventional balloon angioplasty for CLTI patients: Real world experience from Singapore
| Speaker: | Edward Choke, Bukit Merah, Singapore |
14:15 - 14:20
Audience Participation & Discussion
14:20 - 14:25
12-month results from the SWING multicentre study: A novel sirolimus coated balloon for use below-the-knee
| Speaker: | Ramon Varcoe, Sydney, Australia |
14:25 - 14:30
Audience Participation & Discussion
14:30 - 14:35
Update on the RESOLV Study: Bioabsorbable sirolimus coated scaffold for BTK treatment
| Speaker: | Marianne Brodmann, Graz, Austria |
14:35 - 14:40
Audience Participation & Discussion
Bioresorbable Drug-Coated Stents
Time: 14:40 - 15:20
| Anchor: | Roger Greenhalgh, London, United Kingdom |
| Moderators: | Andrew Holden, Auckland, New Zealand |
| Dittmar Boeckler, Heidelberg, Germany |
14:40 - 14:45
An update on the LIFE-BTK randomised trial: Why this trial has become the new gold standard in BTK trials
| Speaker: | Ramon Varcoe, Sydney, Australia |
14:45 - 14:50
Audience Participation & Discussion
14:50 - 14:55
Update on the MOTIV trial: Sirolimus-eluting bioresorbable scaffold for BTK artery disease
| Speaker: | Michel Bosiers, Bern, Switzerland |
14:55 - 15:00
Audience Participation & Discussion
15:00 - 15:05
Update on the EFEMORAL trial: Bioresorbable sirolimus-coated vascular balloon-expandable scaffold for femoropopliteal disease
| Speaker: | Andrew Holden, Auckland, New Zealand |
15:05 - 15:10
Audience Participation & Discussion
15:10 - 15:20
Panel Discussion & Consensus
Sponsored Education
Time: 15:20 - 15:50
Tea Break
Time: 15:50 - 16:10
Peripheral Arterial Consensus Update Continued
Time: 16:10 - 16:50
| Anchor: | Dittmar Boeckler, Heidelberg, Germany |
| Moderators: | Gunnar Tepe, Rosenheim, Germany |
| Marianne Brodmann, Graz, Austria |
16:10 - 16:15
5-years follow-up of subjects with aortoiliac occlusive disease treated with a balloon expandable endoprosthesis
| Speaker: | Andrew Holden, Auckland, New Zealand |
16:15 - 16:20
Audience Participation & Discussion
16:20 - 16:25
Edited Case: Changing compliance and our approach to iliac calcification
| Speaker: | Stefano Fazzini, Rome, Italy |
16:25 - 16:30
Audience Participation & Discussion
16:30 - 16:35
Value of balloon expandable covered stents in treating complex aortoiliac occlusive disease: Advantages and limitations
| Speaker: | Michele Piazza, Padova, Italy |
16:35 - 16:40
Audience Participation & Discussion
16:40 - 16:45
Developing a platform adaptive trial for patients with peripheral arterial disease: The PAEDIS project
| Speaker: | Athanasios Saratzis, Leicester, United Kingdom |
16:45 - 16:50
Audience Participation & Discussion
Chronic Limb Threatening Ischaemia & Hurting Leg Consensus Update
Time: 16:50 - 18:00
| Anchor: | Andrew Holden, Auckland, New Zealand |
| Moderators: | Gunnar Tepe, Rosenheim, Germany |
| Peter Schneider, San Francisco, United States |
16:50 - 16:55
Retrospective PEDAL study using a serration balloon
| Speaker: | Edward Gifford, Connecticut, United States |
16:55 - 17:00
Audience Participation & Discussion
17:00 - 17:05
Preventing thrombosis after infrainguinal arterial bypass surgery with antithrombotic agents - A Delphi consensus study
| Speaker: | Alexander Zimmermann, Zurich, Switzerland |
17:05 - 17:10
Audience Participation & Discussion
17:10 - 17:15
Robustness of mid-term and long-term safety and efficacy after paclitaxel-based endovascular therapy for treatment of femoro-popliteal artery occlusive disease. An updated systematic review
| Speaker: | Mario D'Oria, Trieste, Italy |
17:15 - 17:20
Audience Participation & Discussion
17:20 - 17:25
Stenting BTK in CLTI diabetes mellitus (DM) patients: Preliminary results of the HEAL Registry
| Speaker: | Marco Manzi, Padova, Italy |
17:25 - 17:30
Audience Participation & Discussion
17:30 - 17:35
Follow-up: Peri-procedural standard duplex scan exams may be superior and cheaper as compared to IVUS for most lower extremity arterial cases
| Speaker: | Enrico Ascher, New York, United States |
17:35 - 17:40
Audience Participation & Discussion
17:40 - 17:45
Lower limb sarcopenia on magnetic resonance imaging in patients with diabetes mellitus: A systematic review
| Panel: | Manal Ahmad, London, United Kingdom |
17:45 - 17:50
Audience Participation & Discussion
17:50 - 17:55
Clinical outcomes of sirolimus coated balloons compared with standard balloon angioplasty for patients with chronic limb threatening ischaemia: Twelve-month results from single centre HOPE registry
| Speaker: | Edward Choke, Bukit Merah, Singapore |
17:55 - 18:00
Audience Participation & Discussion